169 filings
8-K
ALKS
Alkermes plc
1 May 24
Alkermes plc Reports First Quarter 2024 Financial Results
7:05am
8-K
ALKS
Alkermes plc
9 Apr 24
Regulation FD Disclosure
7:09am
8-K
ALKS
Alkermes plc
7 Mar 24
Alkermes Announces Appointment of Nancy S. Lurker to Board of Directors
7:09am
8-K
ALKS
Alkermes plc
15 Feb 24
Results of Operations and Financial Condition
7:05am
8-K
ALKS
Alkermes plc
5 Feb 24
Departure of Directors or Certain Officers
4:29pm
8-K
o752d6dz bhm2xpx
8 Jan 24
Regulation FD Disclosure
7:00am
8-K
ugeol31om7vzb5v jh25
14 Dec 23
Alkermes plc Announces Agreement to Sell Athlone, Ireland Facility to Novo Nordisk
6:13am
8-K
33b7bmo1bmjy9mmli
8 Dec 23
Departure of Directors or Certain Officers
4:05pm
8-K
zbn6yf iciakod
15 Nov 23
Alkermes Completes Separation of Oncology Business
7:05am
8-K
fxa o4b4wqk
31 Oct 23
Alkermes Announces Effectiveness of Mural Oncology Form 10 Registration Statement
5:18pm
8-K
5ke0r0mrjo
27 Oct 23
Other Events
5:12pm
8-K
blo2bo
25 Oct 23
Alkermes plc Reports Third Quarter 2023 Financial Results
7:06am
8-K
l4blmhet29ae8bsdy
23 Oct 23
Alkermes Presents First Clinical Data for Orexin 2 Receptor Agonist ALKS 2680 at World Sleep Congress
8:27am
8-K
h95v3grg9vr7kls41s8c
30 Aug 23
Alkermes Announces Settlement With Teva Related to VIVITROL® Patent Litigation
7:14am
8-K
3si01
26 Jul 23
Alkermes plc Reports Second Quarter 2023 Financial Results
7:06am
8-K
04qr57orgtqwmox6
6 Jul 23
Departure of Directors or Certain Officers
8:05am
8-K
toqxrly
5 Jul 23
Entry into a Material Definitive Agreement
5:00pm
8-K
bzupalwx5fqwf
6 Jun 23
Alkermes Announces Final Award in Janssen Pharmaceutica Arbitration and Provides Updated Financial Expectations
6:10am
8-K
0smr m0hqf0qcfmdo
8 May 23
Alkermes Files Preliminary Proxy Statement and Provides Update on Annual Director Nomination Process
5:08pm
8-K
eb23qozo 9b
26 Apr 23
Alkermes plc Reports First Quarter 2023 Financial Results
7:05am